Clinical Trials on Smoldering Multiple Myeloma

Total 12412 results

Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM (HO147SMM)

Smouldering Myeloma

Netherlands, Norway, Czechia, Italy
University College, London
Cancer Research UK

Recruiting

Biology and Genetics of Smouldering Myeloma (COSMOS)

Multiple Myeloma | MGUS | Smouldering Myeloma

United Kingdom
Benovus Bio, Inc.

Unknown

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (BBMPI03)

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Multiple Myeloma (MM) | Smoldering Multiple Myeloma (sMM)

United States
Irene Ghobrial, MD
Janssen Research & Development, LLC

Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Multiple Myeloma | Smoldering Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Multiple Myeloma | High Risk Smoldering Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Smoldering Plasma Cell Myeloma

United States
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Celgene; The Leukemia and Lymphoma Society; Multiple Myeloma... and other collaborators

Completed

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma | Smoldering Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center
HealthTree Foundation

Recruiting

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM)

Multiple Myeloma, Smoldering

United States
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Smoldering Multiple Myeloma (SMM)

Spain
Omar Nadeem, MD
Janssen, LP

Recruiting

DARA RVD For High Risk SMM (PRISM)

Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Icahn School of Medicine at Mount Sinai
Pharmacyclics LLC.

Terminated

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

High Risk Smoldering Multiple Myeloma

United States
Oxford University Hospitals NHS Trust
Amgen

Completed

The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss (LOOMIS)

Myeloma | Smouldering Myeloma | Monoclonal Gammopathy of Undetermined Significance (MGUS)

United Kingdom
Janssen Research & Development, LLC

Completed

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

High-risk Smoldering Multiple Myeloma

United States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Smoldering Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

United States
Carl Ola Landgren, MD, PhD
Janssen Scientific Affairs, LLC

Recruiting

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE)

Multiple Myeloma

United States
University of Utah
Millennium Pharmaceuticals, Inc.

Terminated

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

Cancer | Multiple Myeloma | Myeloma

United States
University of Colorado, Denver

Terminated

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma | Plasmacytosis

United States
Mayo Clinic

Active, not recruiting

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Case Comprehensive Cancer Center

Withdrawn

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Myeloma | Smoldering Myeloma | Monoclonal Gammopathy

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma | Indolent Plasma Cell Myeloma

United States
Rennes University Hospital
Intergroupe Francophone du Myelome

Terminated

Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. (GENOMGUS)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

France
Roswell Park Cancer Institute

Recruiting

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Regeneron Pharmaceuticals

Not yet recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1)

Monoclonal Gammopathy of Undetermined Significance (MGUS) | Smoldering Multiple Myeloma (SMM)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Monoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Monoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

Multiple Myeloma | Amyloidosis | Waldenstrom's Macroglobulinemia | Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
University of Arkansas
Millennium Pharmaceuticals, Inc.

Completed

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

Asymptomatic Multiple Myeloma

United States
NYU Langone Health
Unicorn Pacific Corporation

Terminated

A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Myeloma

United States
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
Sanofi

Active, not recruiting

A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

Plasma Cell Myeloma

Italy, Korea, Republic of, Norway, Canada, Spain, Germany, Greece, Lithuania, Sweden, Israel, Hungary, France, Japan, Australia, China, Denmark, Czechia, Turkey, United States, Brazil, Ireland, New Zealand, Poland, United Kingdom
Jagannath, Sundar, M.D.
Unicorn Pacific Corporation

Terminated

Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma

Multiple Myeloma

United States
University of Utah

Recruiting

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial (SPOTLIGHT)

Smoldering Multiple Myeloma

United States
M.D. Anderson Cancer Center

Recruiting

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Myeloma

United States
National Cancer Institute (NCI)

Terminated

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

Multiple Myeloma | Smoldering Multiple Myeloma | Myeloma

United States
University of Rochester

Recruiting

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Multiple Myeloma | Prostate Cancer | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma (SMM)

United States
Bristol-Myers Squibb
AbbVie

Completed

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Smoldering Multiple Myeloma

United States
Oslo University Hospital
Targovax ASA

Recruiting

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Multiple Myeloma | Smoldering Multiple Myeloma

Norway
University of Rochester
Karyopharm Therapeutics Inc

Recruiting

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
National Cancer Institute (NCI)
Janssen Scientific Affairs, LLC

Active, not recruiting

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Multiple Myeloma

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Multiple Myeloma Research Consortium; Blood Cancer Research...

Completed

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Smoldering Multiple Myeloma

United States

Clinical Trials on Smoldering Multiple Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations